15 June 2011

The Company Announcements Office
ASX Limited

BY E-LODGEENT

Dear Sir/Madam

NOTICE PURSUANT TO SECTION 708AA(2)(f) CORPORATIONS ACT 2001

Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby gives to the ASX, as the relevant market operator, the attached notice in accordance with section 708AA(7) in compliance with section 708AA(2)(f).

By Order of the Board

Yours sincerely

[Signature]

Mr Rob Turnbull
Chief Financial Officer
Neuren Pharmaceuticals Limited
ARBN 111 496 130

RIGHTS ISSUE NOTICE UNDER SECTION 708AA(2)(f)
OF THE CORPORATIONS ACT 2001

NEUREN PHARMACEUTICALS LIMITED (COMPANY) IS TO UNDERTAKE A RIGHTS ISSUE OF
617,887,310 ORDINARY SHARES TO ITS MEMBERS (ISSUE) ON THE BASIS OF AN
ENTITLEMENT TO SUBSCRIBE FOR ONE ORDINARY SHARE FOR EACH SHARE HELD AS AT
THE RECORD DATE OF 27 JUNE 2011 WITH EACH SUCH SHARE BEING ISSUED AT AN ISSUE
PRICE OF A$0.013 TO RAISE UP TO APPROXIMATELY A$8.0 MILLION.

The Company states that it will offer the shares for issue without disclosure to investors under Part 6D.2
of the Corporations Act 2001 (Act) and states that this notice is given to ASX under paragraph
708AA(2)(f) of the Act in compliance with the requirements of sub-section 708AA(7) of the Act.

1. The Company advises:
   (a) the shares will be offered under a rights issue as defined in the Act;
   (b) the shares are in a class of securities, being fully paid ordinary shares, that are quoted
       securities at the time at which the offer will be made;
   (c) trading on the stock market conducted by ASX Limited in that class of securities referred to in
       (b) above (being the fully paid ordinary shares in the capital of the Company) was not
       suspended for more than a total of 5 days during the shorter of the following periods:
       (i) the period during which the class of securities is quoted;
       (ii) the period of 12 months before the day on which the offer is made;
   (d) no exemption under section 111AS or 111AT of the Act covered the Company, or any person
       as director or auditor of the Company, at any time during the period of 12 months before the
       day on which the offer will be made, being the relevant period referred to in paragraph (c);
   (e) no order under section 340 or 341 of the Act covered the Company, or any person as a director
       or auditor of the Company, at any time during the relevant period referred to in paragraph (c).

2. For the purposes of section 708AA(7)(c) of the Act the Company gives notice that as at the date of
   this notice the Company has complied with:
   (a) the provisions of Chapter 2M of the Act as they apply to the Company;
   (b) section 674 of the Act.

3. As at the date of this notice there is no excluded information being information:
   (a) that has been excluded from a continuous disclosure notice in accordance with the Listing
       Rules of ASX; and
   (b) that investors and their professional advisers would reasonably require for the purpose of
       making an informed assessment of:
       (i) the assets and liabilities, financial position and performance, profits and losses and
           prospects of the Company; or
       (ii) the rights and liabilities attaching to the Shares.

4. The issue of shares under the rights issue is not expected to have any effect on the control of the
   Company.

Dated this 15th day of June 2011

By Order of the Board

[Signature]

Mr Rob Turnbull
Chief Financial Officer
Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited
ARBN 111 496 130